Back to CS Candriam S.C.A.
ARWR
Showing 1 of 23 quarters
Position history for CSCandriam S.C.A.'s holdings in ARROWHEAD PHARMACEUTICALS IN
No. Candriam S.C.A. exited its ARWR (Arrowhead Pharmaceuticals in) position in Q3 2024. Its Q2 2024 13F listed 228,054 shares worth $5.9M. Candriam S.C.A. already held ARWR in its Q1 2019 13F, the earliest on record, and held it in 22 quarterly 13F filings.
Final Value
$0
Final Shares
0
Total Value Change
$0
Total Shares Change
0
Quarter-by-Quarter History